Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Obesity Medicine
Why is it recommended to switch to a non-oral contraceptive or add a barrier method of contraception for 4 weeks after tirzepatide initiation but not with semaglutide?
Related Questions
In patients with iron deficiency due to history of gastric bypass or IBD, would you consider oral iron therapy if the iron deficiency anemia is mild?
Can procalcitonin be used as a marker for endothelial dysfunction emanating from chronic inflammation of obesity?
How do you decide between bariatric surgery and a GLP-1 receptor agonist for patients with metabolic dysfunction-associated steatotic liver disease who have not met weight loss goals after six months of lifestyle interventions?
Would you consider changing a non-diabetic patient with obesity and a history of CAD who is on semaglutide to tirzepatide if they have not achieved their weight loss goals?
Are you more likely to recommend medical management for obesity instead of bariatric surgery in patients with preexisting hypothyroidism, given a recent study showing increased risks of complications?
How long do you typically treat patients with phentermine for weight loss and what clinical markers do you follow?
Do you recommend restarting GLP-1RA after bariatric surgery if they tolerated it before the surgery?
Should orlistat be avoided in patients with a history of kidney stones?
When treating fatty liver disease with resmetirom, how often should a FibroScan be repeated to assess treatment response?
Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?
